BR112022013620A2 - Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos - Google Patents

Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos

Info

Publication number
BR112022013620A2
BR112022013620A2 BR112022013620A BR112022013620A BR112022013620A2 BR 112022013620 A2 BR112022013620 A2 BR 112022013620A2 BR 112022013620 A BR112022013620 A BR 112022013620A BR 112022013620 A BR112022013620 A BR 112022013620A BR 112022013620 A2 BR112022013620 A2 BR 112022013620A2
Authority
BR
Brazil
Prior art keywords
glycoprotein
methods
adenoviral vectors
vectors encoding
viral antigens
Prior art date
Application number
BR112022013620A
Other languages
English (en)
Portuguese (pt)
Inventor
Cj Ertl Hildegund
Stephen Magowan Colin
Original Assignee
Virion Therapeutics Llc
The Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virion Therapeutics Llc, The Wistar Inst filed Critical Virion Therapeutics Llc
Publication of BR112022013620A2 publication Critical patent/BR112022013620A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112022013620A 2020-01-09 2021-01-08 Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos BR112022013620A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062958827P 2020-01-09 2020-01-09
US202062958809P 2020-01-09 2020-01-09
US202062967104P 2020-01-29 2020-01-29
US202062967242P 2020-01-29 2020-01-29
US202063064571P 2020-08-12 2020-08-12
US202063064506P 2020-08-12 2020-08-12
US202063112202P 2020-11-11 2020-11-11
US202063112219P 2020-11-11 2020-11-11
PCT/US2021/012630 WO2021142212A1 (en) 2020-01-09 2021-01-08 Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same

Publications (1)

Publication Number Publication Date
BR112022013620A2 true BR112022013620A2 (pt) 2022-09-13

Family

ID=74505354

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013620A BR112022013620A2 (pt) 2020-01-09 2021-01-08 Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos

Country Status (13)

Country Link
US (5) US12605444B2 (cg-RX-API-DMAC7.html)
EP (1) EP4087605A1 (cg-RX-API-DMAC7.html)
JP (2) JP7696909B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220163354A (cg-RX-API-DMAC7.html)
CN (2) CN115335076B (cg-RX-API-DMAC7.html)
AU (1) AU2021205936A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022013620A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166989A1 (cg-RX-API-DMAC7.html)
IL (1) IL294387A (cg-RX-API-DMAC7.html)
MX (1) MX2022008572A (cg-RX-API-DMAC7.html)
PH (1) PH12022551648A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021142212A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202310905B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115335076B (zh) * 2020-01-09 2025-10-28 病毒治疗有限责任公司 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法
WO2026093412A2 (en) * 2024-10-29 2026-05-07 Nec Oncoimmunity As Hbv vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012502A2 (en) 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
US20090246220A1 (en) * 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
EP2959915A1 (en) * 2014-06-23 2015-12-30 Institut Pasteur A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
CN105367662B (zh) * 2014-08-29 2021-03-12 汤正好 一种hbv相关的融合蛋白、其制备方法及其应用
WO2017176319A1 (en) * 2016-04-06 2017-10-12 University Of Washington Therapeutic vaccine for hepatitis b virus (hbv) using the hbv core antigen
EP3490610A4 (en) 2016-08-01 2020-05-20 The Wistar Institute Of Anatomy And Biology COMPOSITIONS AND METHODS FOR REPLICATION-DEFICIENT ADENOVIRAL VECTORS FOR VACCINE APPLICATIONS
HRP20241379T1 (hr) * 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
CN115335076B (zh) * 2020-01-09 2025-10-28 病毒治疗有限责任公司 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法

Also Published As

Publication number Publication date
EP4087605A1 (en) 2022-11-16
MX2022008572A (es) 2022-09-23
JP7696909B2 (ja) 2025-06-23
US12605444B2 (en) 2026-04-21
AU2021205936A1 (en) 2022-07-21
IL294387A (en) 2022-08-01
US20230063089A1 (en) 2023-03-02
US20240091347A1 (en) 2024-03-21
ZA202310905B (en) 2025-06-25
US20250228934A1 (en) 2025-07-17
KR20220163354A (ko) 2022-12-09
US12290561B2 (en) 2025-05-06
JP2025124904A (ja) 2025-08-26
JP2023510544A (ja) 2023-03-14
CA3166989A1 (en) 2021-07-15
WO2021142212A1 (en) 2021-07-15
CN121221754A (zh) 2025-12-30
US11291716B2 (en) 2022-04-05
US20220175913A1 (en) 2022-06-09
CN115335076B (zh) 2025-10-28
US11850282B2 (en) 2023-12-26
PH12022551648A1 (en) 2024-02-12
US20210393770A1 (en) 2021-12-23
CN115335076A (zh) 2022-11-11

Similar Documents

Publication Publication Date Title
CO2021013878A2 (es) Vectores de virus adenoasociado recombinantes
MX2021003175A (es) Vacuna contra el virus de la peste porcina africana.
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
BR112022016550A2 (pt) Proteínas de ligação a flt3 e métodos de uso
CL2020002960A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
AR056138A1 (es) Procedimiento para la expresion recombinante de un polipeptido
DK11789D0 (da) Rekombinante vaccinia-vira
DK0596979T3 (da) Rekombinante nucleinsyrer fra plantevirus
ZA202310905B (en) Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same
CR20200170A (es) Receptores de células t que reconocen p53 mutado
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
MX2021015465A (es) Vacuna para fiebre porcina africana.
WO2021198706A3 (en) Coronavirus vaccines
ES2150416T3 (es) Vacuna virica defectiva producida por una linea celular complementada en trans.
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
ES2061708T3 (es) Virus recombinante de la viruela de la gallina, vectores de expresion de proteinas heterologas y vacunas para aves de corral derivadas de este virus.
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
BR112022011099A2 (pt) Tratamento de doenças relacionadas ao vírus da hepatite b
FI3445397T3 (fi) Integraalisen membraaniproteiinin näyttö poxviruksen solunulkoisilla vaipallisilla virioneilla
DE3853139D1 (de) Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
MX2022014943A (es) Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.
PE20190966A1 (es) Factor viii direccionado a los globulos rojos y metodo para su uso
ES2072928T3 (es) Antigenos de celulas de islotes pancreaticos obtenidos por clonaje molecular.
ES2058486T3 (es) Inmunogenos nativos y recombinantes del grupo b de eimeria tenella utiles como vacunas para las coccidiosis.
UY36616A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos